Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

BACKGROUND: Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immunomodulatory mechanisms of action, demonstrated clinical benefit as monotherapy or in combination with established regimens in patients with multiple myeloma with one or more prior lines of therapy. CASE PRESE...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Exp Hematol Oncol
Asıl Yazarlar: Usmani, Saad Z., Khan, Imran, Chiu, Christopher, Foureau, David, Druhan, Lawrence J., Rigby, Katherine, Casneuf, Tineke, Sasser, A. Kate
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2018
Konular:
Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5804097/
https://ncbi.nlm.nih.gov/pubmed/29445583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-018-0096-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller